Clinical trials
Breast Cancer Patients clinical trials
Below are recruiting breast cancer patients clinical trials, each written for real people, not researchers. We’re tracking 2,247 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06405269Enrolling by invitation
How breast cancer treatment affects cholesterol in young women
This study looks at how chemotherapy, hormone therapy, or targeted therapy affects cholesterol levels in younger women with early-stage breast cancer that can be removed with surgery. It may help doctors understand how to better manage heart health during cancer treatment.
Beijing, Beijing MunicipalityAges 18–40 - NCT06223022Enrolling by invitation
Nurse phone calls after cancer treatment ends
This trial tests whether regular phone calls from a nurse can help patients after they finish their main cancer treatment. It focuses on breast, colorectal, or prostate cancer that was treated with a goal to cure.
UmeåAges 18 years+ - NCT04203849Enrolling by invitation
Study of breast cancer patients getting radiotherapy
This study follows breast cancer patients who are scheduled to receive radiotherapy at a National Cancer Center in Korea. By collecting information during and after treatment, researchers hope to better understand how patients do over time.
Goyang-si, Gyeonggi-doAges 20 years+ - NCT04098640Enrolling by invitation
Testing tumor DNA in younger people with metastatic breast cancer
This study looks at your tumor’s molecular (DNA/biologic) features to better understand metastatic breast cancer in people under 50. You may help researchers by providing tissue samples (biopsies) for lab testing.
Seoul, SeoulAges 19–50 - NCT07706556Recruiting
Remote activity program for breast cancer survivors
This trial tests a new program to help breast cancer survivors become more active. The program is delivered remotely using a smartphone app, and it adjusts based on your progress. It may be a good fit if you finished treatment less than 5 years ago and are not very active yet.
Lebanon, New HampshireAges 18 years+ - NCT07117214RecruitingPhase 1
Study of a new imaging agent for breast and lung cancers
This trial tests a new imaging agent called [68Ga]Ga-DWJ155 to see how well it helps detect certain types of advanced breast cancer and non-small cell lung cancer. It may help doctors better understand the cancer and guide treatment decisions.
Groningen, Provincie GroningenAges 18–100 - NCT06067503RecruitingPhase 2
PET scan to detect hormone therapy resistance in breast cancer
This trial tests a new PET scan (called FFNP) to see if it can find which breast cancers stop responding to hormone therapy early. It's for people with advanced hormone-receptor-positive breast cancer who are starting a new endocrine treatment.
Madison, WisconsinAges 18 years+ - NCT05501704RecruitingPhase 2
Testosterone-blocking therapy for male breast cancer
This Phase 2 study tests an oral treatment (called “ET”) to treat hormone-receptor–positive, HER2-negative invasive breast cancer in men. It may help shrink or control cancer without using standard cancer treatments first.
Washington D.C., District of ColumbiaAges 18 years+ - NCT05876065Recruiting
Maintenance chemotherapy to help control advanced breast cancer
This trial studies whether taking a combination of capecitabine and cyclophosphamide after your best prior treatment can help keep advanced breast cancer from growing. It may help people whose disease has already responded or is stable after “salvage” treatment.
ShanghaiAges 18 years+ - NCT07427394RecruitingPhase 2
Camizestrant and atirmociclib for advanced breast cancer
This trial tests two experimental drugs—camizestrant and atirmociclib—for women with advanced ER-positive breast cancer that has worsened after prior treatment. The goal is to see if the combination is safe and tolerable.
St Louis, MissouriAges 18 years+ - NCT02102165Recruiting
Study samples from metastatic triple-negative breast cancer
This study looks at tumor “clues” by using tissue and blood samples in people with metastatic breast cancer (with specific subtype). It aims to better understand what drives the cancer, which may help guide future treatments.
BrusselsAges 18 years+ - NCT05398861RecruitingPhase 2
Testing utidelone plus bevacizumab for HER2-negative advanced breast cancer
This trial studies whether utidelone combined with bevacizumab can shrink tumors and slow progression in women with advanced HER2-negative breast cancer that has already been treated at least twice. It may help people who have limited options after earlier chemotherapy and/or hormone (endocrine) treatments.
Zhengzhou, HenanAges 18–70 - NCT05256745RecruitingPhase 1/Phase 2
A medicine to protect the heart during breast cancer chemotherapy
This early-phase study tests azeliragon to lower the risk of chemotherapy-related heart damage in women with early-stage breast cancer. Participants get their planned standard chemotherapy, plus the study medicine, and are monitored for safety and heart health.
Washington D.C., District of ColumbiaAges 18 years+ - NCT04824014RecruitingPhase 2
PET imaging for ER+ advanced breast cancer
This trial uses a special PET scan called 4FMFES-PET to take detailed pictures of ER-positive breast cancer that has spread. It helps doctors see where the cancer is and how active it is, which may guide treatment decisions.
Sherbrooke, QuebecAges 18 years+ - NCT04680715RecruitingPhase 2
Tested radiation before and after breast surgery in older women
This Phase 2 trial looks at a specific radiation timing and technique around the time of breast-conserving surgery. It may help reduce the chance the cancer comes back in selected older patients with certain early-stage, hormone-positive, HER2-negative breast cancers.
Clermont-FerrandAges 65 years+ - NCT07299825RecruitingPhase 2
Study of A166 for advanced HER2-positive breast cancer
This trial tests a new drug called A166 for people with HER2-positive breast cancer that has spread or can't be removed. It is for those who have already tried up to five treatments, including a specific type of HER2 antibody-drug conjugate.
Zhenzhou, HenanAges 18–75 - NCT05831878Recruiting
Drug RC48 for HER2-low or HER2-ultralow breast cancer
This trial tests RC48, an antibody-drug treatment, for people with advanced breast cancer that cannot be cured or removed, specifically HER2-low (or HER2-ultralow) tumors. It may help by targeting cancer cells with this “HER2-low” trait while limiting spread in the body.
ShanghaiAges 18 years+ - NCT07591090RecruitingPhase 2
Drug combination study for advanced HER2-negative breast cancer
This study tests whether combining two new drugs (AK146D1 and AK112) can help people with advanced breast cancer that is HER2-negative (a type that doesn't have too much of a specific growth protein). The goal is to see if this combination can shrink tumors and improve survival.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07180264Recruiting
Trastuzumab deruxtecan for advanced breast cancer
This trial tests a targeted therapy called trastuzumab deruxtecan for people with advanced breast cancer. It aims to see how well the treatment works and how safe it is.
ShanghaiAges 18 years+ - NCT07389733RecruitingPhase 1/Phase 2
Study of HRS-6208 with other drugs for advanced breast cancer
This trial tests a new combination of drugs (HRS-6208 with HRS-8080, fulvestrant, or letrozole) for people with advanced or metastatic breast cancer that cannot be removed by surgery. It aims to see if these combinations can help shrink or slow the cancer.
Dalian, LiaoningAges 18–75 - NCT05982678RecruitingPhase 2
Study of a drug for breast cancer that has spread to a few spots
This trial tests a drug for people with HER2-positive breast cancer that has spread to only a few places in the body (up to 5 spots). It aims to see if the treatment works well before starting stronger therapies.
AmsterdamAges 18 years+ - NCT06433609RecruitingPhase 2
ADC plus immunotherapy for advanced HER2-negative breast cancer
This trial tests a combination of an antibody-drug conjugate (ADC) and an immunotherapy drug (adebrelimab) for people with advanced HER2-negative breast cancer that has stopped responding to prior treatments. The goal is to see if this combination can help shrink or slow the cancer.
Beijing, Beijing MunicipalityAges 18–75 - NCT07340424RecruitingEarly Phase 1
Study of 225Ac-TR2205 for triple-negative breast cancer
This trial tests a new radioactive drug called 225Ac-TR2205 for people with triple-negative breast cancer that has spread. The goal is to see if it is safe and tolerable. It may be an option if you have tried at least two other treatments, including one for metastatic disease.
Jinan, ShandongAges 18 years+ - NCT07673029RecruitingPhase 3
Comparing two treatments for HER2-positive breast cancer
This trial compares a new drug, GQ1005, with an existing treatment called T-DM1 for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. The goal is to see which one works better for those who have already received certain other treatments.
Bengbu, AnhuiAges 18–75
Hear when a new Breast Cancer Patients trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer patients?
- Yes. Clin2 currently lists 2,247 recruiting breast cancer patients studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer patients trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer patients trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.